Mirna Pushes Series B, First IND Guidance to 2012 | GenomeWeb

By Doug Macron

Mirna Therapeutics has pushed back to next year the anticipated filing date for its first investigational new drug application as it continues to work to close a Series B financing round, a company official told Gene Silencing News this week.

At the same time, Mirna has gained some traction in its efforts to form an industry partnership, having inked technology-evaluation deals with two pharmaceutical companies, Mirna President and CEO Paul Lammers said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.